Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Metformin has had a 'black box' contraindication in diabetic patients with heart failure (HF), but many believe it to be the treatment of choice in this setting. Therefore, we attempted to conduct a pilot study to evaluate the feasibility of undertaking a large randomized controlled trial with clinical endpoints. STUDY DESIGN: The pilot study was a randomized double blinded placebo controlled trial. Patients with HF and type 2 diabetes were screened in hospitals and HF clinics in Edmonton, Alberta, Canada (population ~1 million). Major exclusion criteria included the current use of insulin or high dose metformin, decreased renal function, or a glycosylated hemoglobin <7%. Patients were to be randomized to 1500 mg of metformin daily or matching placebo and followed for 6 months for a variety of functional outcomes, as well as clinical events. RESULTS: Fifty-eight patients were screened over a six month period and all were excluded. Because of futility with respect to enrollment, the pilot study was abandoned. The mean age of screened patients was 77 (SD 9) years and 57% were male. The main reasons for exclusion were: use of insulin therapy (n = 23; 40%), glycosylated hemoglobin <7% (n = 17; 29%) and current use of high dose metformin (n = 12; 21%). Overall, contraindicated metformin therapy was the most commonly prescribed oral antihyperglycemic agent (n = 27; 51%). On average, patients were receiving 1,706 mg (SD 488 mg) of metformin daily and 12 (44%) used only metformin. CONCLUSION: Despite uncertainty in the scientific literature, there does not appear to be clinical uncertainty with regards to the safety or effectiveness of metformin in HF making a definitive randomized trial virtually impossible. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00325910.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 3×
“We planned a dosage titration protocol where patients would be instructed to slowly titrate their study medication to a maximum dose of 1500 mg per day over a 3 week period based on a published titration protocol[1].”
The Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812 · cited 1×
“Diabetes is a common comorbidity in patients with heart failure and portends a particularly poor prognosis[9,10].”
Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1614 · Cited by 600
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458 · cited 5×
“Furthermore, observational data in Canada, Europe, and the US have shown that 20 to 25% of patients receiving metformin therapy also have comorbid heart failure[4,11,17,20,23,31,32] and US data has indicated that the use of metformin has increased by over 50% in patients with heart failure in recent years[12].”
InfluentialJohnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citationImproved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419 · cited 6×
“Furthermore, observational data in Canada, Europe, and the US have shown that 20 to 25% of patients receiving metformin therapy also have comorbid heart failure[4,11,17,20,23,31,32] and US data has indicated that the use of metformin has increased by over 50% in patients with heart failure in recent years[12].”
InfluentialSelf-citationFactors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390 · cited 1×
“The inability to enroll patients into the pilot study may have been influenced by numerous factors including the patient-clinician relationship and the perceived importance of the trial[34].”
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2594 · Cited by 312
Smooke, S., Horwich, T. B., & Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.005 · Cited by 196
Randomised clinical trials in general practice: lessons from a failure.
Tognoni, G., Alli, C., Avanzini, F., Bettelli, G., Colombo, F., Corso, R., Marchioli, R., & Zussino, A. (1991) · BMJ · doi:10.1136/bmj.303.6808.969 · Cited by 139 · cited 1×
“Although all clinicians directly involved in our study were supportive, those outside of the study may not have believed the research question was of interest or importance[37].”
Cited by
Eurich, D. T., Weir, D. L., Majumdar, S. R., Tsuyuki, R. T., Johnson, J. A., Tjosvold, L., Vanderloo, S. E., & McAlister, F. A. (2013) · Circulation: Heart Failure · doi:10.1161/circheartfailure.112.000162 · Cited by 341
Self-citationBugge, C., Williams, B., Hagen, S., Logan, J., Glazener, C., Pringle, S., & Sinclair, L. (2013) · Trials · doi:10.1186/1745-6215-14-353 · Cited by 175
Metformin Therapy and Outcomes in Patients With Advanced Systolic Heart Failure and Diabetes
Shah, D. D., Fonarow, G. C., & Horwich, T. B. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.10.022 · Cited by 100
Metformin and heart failure: never say never again
Papanas, N., Maltezos, E., & Mikhailidis, D. P. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.638283 · Cited by 39
Metadata
- Authors
- Eurich, D. T., Tsuyuki, R. T., Majumdar, S. R., McAlister, F. A., Lewanczuk, R., Shibata, M. C., & Johnson, J. A.
- Venue
- Trials
- Published
- 2009-02-09
- Volume
- 10
- Issue
- 1
- Pages
- 12-12
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2091475095
- Cited by
- 55
- References
- 11
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. https://app.cochat.ai/papers/10.1186/1745-6215-10-12
- The paper
- Eurich, D. T., Tsuyuki, R. T., Majumdar, S. R., McAlister, F. A., Lewanczuk, R., Shibata, M. C., & Johnson, J. A. (2009). Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials. https://doi.org/10.1186/1745-6215-10-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.